825AC0F8-4D16-4109-AA6A-4648934E3C35
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.54927726675427
- age_years
- 81
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.594
- TNFA_SIGNALING_VIA_NFKB+0.572
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- MTORC1_SIGNALING+0.492
- IL6_JAK_STAT3_SIGNALING+0.485
- MYC_TARGETS_V1+0.484
- APOPTOSIS+0.481
- MYC_TARGETS_V2+0.478
- TGF_BETA_SIGNALING+0.448
- INTERFERON_GAMMA_RESPONSE+0.446
Top 10 suppressed
- KRAS_SIGNALING_DN-0.431
- SPERMATOGENESIS-0.322
- PANCREAS_BETA_CELLS-0.229
- MYOGENESIS-0.072
- BILE_ACID_METABOLISM-0.012
- WNT_BETA_CATENIN_SIGNALING+0.000
- ESTROGEN_RESPONSE_LATE+0.023
- HEME_METABOLISM+0.038
- APICAL_SURFACE+0.054
- ESTROGEN_RESPONSE_EARLY+0.057
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.987 |
| 2 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.985 |
| 3 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.984 |
| 4 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.984 |
| 5 | SRR934913 | — | — | 0.982 |
| 6 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.981 |
| 7 | F9EB85A8-8E6D-44C0-8C59-50B1DB4E652B | — | — | 0.981 |
| 8 | D8A3D7E7-BDC0-42FF-B451-E25F472E8612 | — | — | 0.978 |
| 9 | SRR934965 | — | — | 0.978 |
| 10 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.975 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.594 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.572 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.492 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.485 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.484 | Inavolisib | — uncovered |
| APOPTOSIS | 0.481 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.478 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.448 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.446 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| HYPOXIA | 0.422 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.421 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.413 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.405 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.393 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.387 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.383 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.376 | Idelalisib | — uncovered |